Regeneron Pharmaceuticals, Inc.
http://www.regeneron.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Regeneron Pharmaceuticals, Inc.
Regeneron’s Libtayo/Fianlimab LAGs Bristol’s Opdualag On Timing, But May Win On Efficacy
The PD-1/LAG-3 combination showed a high response rate in a small number of melanoma patients with prior PD-1 exposure.
Pharma vs The IRA — Industry Leaders React To Merck Lawsuit
Execs offer a guarded reaction, noting the need for continued dialogue, but emphasize the dire threat that the pricing program poses to the pharma business model.
Pharma vs The IRA — Industry Leaders React To Merck Lawsuit
Execs offer a guarded reaction, noting the need for continued dialogue, but note the dire threat that the pricing program poses to the pharma business model.
Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ASCO
Regeneron presented data for linvoseltamab, while Pfizer presented data for elranatamab, including in patients who previously received BCMA-directed therapy.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Checkmate Pharmaceuticals, Inc.
- Regeneron Genetics Center LLC (RGC)
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice